Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Breast Cancer Res Treat. 2016 Feb 9;155(3):431–440. doi: 10.1007/s10549-016-3698-y

Fig. 2.

Fig. 2

Effect of targeting HER3 or β1 integrin on in vivo growth of HCC1569 tumors. Nude mice bearing HCC1569TR-shHER3 tumor xenografts were randomly assigned to one of four treatment arms consisting of control (n = 11), oral doxycycline (200 ug/ml) in drinking water (n = 12), AIIB2 administered twice weekly IP (1 mg/kg) (n = 12), or both (n = 12). Treatments were terminated after three weeks and the mice were continuously monitored thereafter in the post-treatment phase. Error bars indicated the standard error of the mean